Your MedClueRx DNA samples are processed at NorthShore laboratories and analyzed by specialists at our Pharmacogenomics Clinic.
The MedClueRx program and Pharmacogenomics Clinic is led by Mark Dunnenberger, PharmD, Director of Pharmacogenomics. He received his PharmD from the University of Tennessee, trained in pharmacy practice at Mission Health in Asheville, NC, and completed a second year pharmacy residency in clinical pharmacogenetics at St Jude Children’s Research Hospital. In 2014 he received the Presidential Trainee Award from the American Society for Clinical Pharmacology and Therapeutics for his work on the clinical implementation of pharmacogenetics while at St. Jude. He is also a board certified pharmacotherapy specialist.
Dr. Dunnenberger is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC is an international organization that publishes guidelines on how to use pharmacogenetic data in clinical practice. He has co-authored several CPIC guidelines including the guidelines for CYP2D6/codeine and HLA-B/carbamazepine. His research interests include translating pharmacogenomics into clinical practice, developing information technology solutions for delivering genetic information to both clinicians and patients in a practical manner, and evaluating methods for educating healthcare professionals about pharmacogenetics.
Dyson Wake, PharmD, serves the MedClueRx program as Senior Clinical Specialist. He received his PharmD from the Drake University College of Pharmacy in 2014. He completed a PGY1 pharmacy practice residency at Memorial Hospital in South Bend, IN, and completed a PGY2 clinical pharmacogenomics residency through the University of Florida College of Pharmacy in Gainesville, FL.
Dr. Wake has co-authored four original publications and two manuscripts including Cost Avoidance Analysis of a Hospital Medication Assistance Program (May 2015) and UF Health PMP: Value of Preemptive Pharmacogenetic Testing (June 2016).
Annette Walsh Sereika is the Administrative Director of Research at the Center for Molecular Medicine, focusing on the MedClueRx program. She earned a Master of Science in Nursing with Honors, with post graduate certification as an Adult Nurse Practitioner from Loyola University, Marcella Niehoff School of Nursing in 2011.
In over 30 years of work in NeuroOncology, Sereika was involved in numerous clinical trials and advancements in treatments of patients with brain tumors. She continues the effort to implement safer and more effective treatments through pharmacogenomics.